SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-23-000013
Filing Date
2023-04-06
Accepted
2023-04-06 11:24:15
Documents
8
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 6-K a2023informationcircularfo.htm 6-K 20237
2 EX-99.1 onc-2023circularfinal.htm EX-99.1 499442
3 EX-99.2 oncolytics-proxy2023fina.htm EX-99.2 11027
4 image_0a.jpg GRAPHIC 74787
5 image_1a.jpg GRAPHIC 15395
6 image_4a.jpg GRAPHIC 107818
7 oncolytics-proxy2023fina001.jpg GRAPHIC 206169
8 oncolytics-proxy2023fina002.jpg GRAPHIC 215422
  Complete submission text file 0001129928-23-000013.txt   1384702
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 23804958
SIC: 2834 Pharmaceutical Preparations